[The effect of recombinant human erythropoietin on postoperative anemia in orthognathic patients].
OBJECTIVE
To observe the effect of rhEPO on postoperative anemia in orthognathic patients.


METHODS
31 patients had 500-1200 ml blood loss during orthognathic operation, who were divided into two groups randomly, the experiment group and the control group. The patients in the experiment group received rhEPO 6000IU subcutaneously for 3 times in a week and Ferrost sulfatis Et vitamini-medtech 1 tablet per day via oral administration for 12 days after operation, while the patients in the control group only received the same dose of Ferrost sulfatis Et vitamini-medtech. The loss of blood of the patients during operation were estimated and recorded. Their Hb and Hct were mensured before operation, and in the first, third, seventh-twelfth day after operation.


RESULTS
In the twelfth day after operation, the Hb and Hct of the patients in the experiment group had a significantly higher increase than that in the control group (P<0.05).


CONCLUSIONS
rhEPO combined Ferrost sulfatis Et vitamini-medtech are suitable to apply in orthognathic patients with anemia after operation, which may effectively accelerate the recovery of their anemia, and avoid transfusion of blood.
Xu
Hui
H
Department of Anesthesiology, Ninth People's Hospital, Shanghai Second Medical University. Shanghai 200011, China.
Yan
Wei-Min
WM
Gen
Qing-Sheng
QS
Jiang
Hong
H
Zhu
Ye-Shen
YS
D000293:Adolescent; D000328:Adult; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D004921:Erythropoietin / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008334:Mandible / Q000601:surgery*; D011183:Postoperative Complications / Q000188:drug therapy*; D011994:Recombinant Proteins
D011994:Recombinant Proteins; D004921:Erythropoietin